FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2293366814> ?p ?o ?g. }

• W2293366814 abstract "Abstract Acute and chronic leukemias, including CD34+ CML stem cells, overexpress the Wilms tumor gene 1 (WT1) protein, making WT1 an attractive therapeutic target. ESKM is a fully human IgG1 antibody that targets a 9 amino acid sequence (RMF) of the protein WT1 in the context of HLA-A0201, allowing it to target an undruggable, widely expressed, intracellular oncogene product. BV173 is an HLA-A0201+, human Ph+ ALL cell line that expresses WT1, and tagged by our lab with luciferase. We engineered a tyrosine kinase inhibitor (TKI) resistant BV173-R cell line by transducing BV173 with the resistant T315I Bcr-Abl plasmid. Antibody-dependent cellular cytotoxicity (ADCC) was evaluated in vitro by chromium release assay, utilizing human PBMC effectors. Tumor growth in vivo was assessed in NOD/SCID gamma (NSG) mice with bioluminescence imaging (BLI). RT-PCR was used to evaluate minimal residual disease in mice with negative BLI signal at the end of therapy. Imatinib, dasatinib, and ponatinib were used at up to maximally tolerated doses, given IP once daily. ESKM was administered at 100 µg twice weekly IP. ESKM mediated ADCC against both BV173 and BV173-R cell lines in vitro. In a BV173 engrafted human leukemia xenograft model, ESKM was more potent than imatinib, with median tumor growth reduction of 78% vs 52%. Combination of imatinib and ESKM therapy resulted in a 94% reduction in leukemic growth. High dose dasatinib (40 mg/kg daily) was more potent than ESKM, but discontinuation of therapy due to dasatinib toxicity resulted in relapse. Combination with ESKM therapy with dasatinib resulted in cure in 75% of mice, confirmed by bone marrow RT-PCR three weeks after termination of therapy. For mice cytoreduced with dasatinib followed by consolidation therapy with ESKM, delayed relapse was observed, but no cures. ESKM was highly superior to imatinib and dasatinib against the T315I BV173-R leukemia in vivo. Cures were not achieved with combination therapy of ESKM and either first or second generation TKIs against resistant T315I leukemia. Ponatinib at 10 mg/kg had higher efficacy than ESKM alone against BV173-R, but mice treated with combination of ESKM and ponatinib had superior tumor reduction. CONCLUSION: ESKM is an effective therapeutic antibody for sensitive and T315I Ph+ ALL. Resistant T315I Ph+ leukemic growth is inhibited more effectively by ESKM therapy compared to imatinib and dasatinib, and combination therapy with ESKM is superior to ponatinib. Supported by the Leukemia and Lymphoma Society, NIH R01CA55349, P01 23766 and T32CA62948-18. Disclosures: Yan: Eureka Therapeutics: Employment. Liu:Eureka Therapeutics: Employment, Equity Ownership." @default.
• W2293366814 created "2016-06-24" @default.
• W2293366814 creator A5006680533 @default.
• W2293366814 creator A5029624769 @default.
• W2293366814 creator A5035010583 @default.
• W2293366814 creator A5042026897 @default.
• W2293366814 creator A5060851233 @default.
• W2293366814 creator A5062508226 @default.
• W2293366814 creator A5075653007 @default.
• W2293366814 date "2013-11-15" @default.
• W2293366814 modified "2023-09-27" @default.
• W2293366814 title "Therapeutic Efficacy and Cure Of Sensitive and T315I Pan-Resistant Human Ph+ Leukemia In Mice Using a TCR-Like Antibody To WT1/HLA-A0201 Alone, Or In Combination With Tyrosine Kinase Inhibitors" @default.
• W2293366814 doi "https://doi.org/10.1182/blood.v122.21.855.855" @default.
• W2293366814 hasPublicationYear "2013" @default.
• W2293366814 type Work @default.
• W2293366814 sameAs 2293366814 @default.
• W2293366814 citedByCount "0" @default.
• W2293366814 crossrefType "journal-article" @default.
• W2293366814 hasAuthorship W2293366814A5006680533 @default.
• W2293366814 hasAuthorship W2293366814A5029624769 @default.
• W2293366814 hasAuthorship W2293366814A5035010583 @default.
• W2293366814 hasAuthorship W2293366814A5042026897 @default.
• W2293366814 hasAuthorship W2293366814A5060851233 @default.
• W2293366814 hasAuthorship W2293366814A5062508226 @default.
• W2293366814 hasAuthorship W2293366814A5075653007 @default.
• W2293366814 hasConcept C126322002 @default.
• W2293366814 hasConcept C159654299 @default.
• W2293366814 hasConcept C203014093 @default.
• W2293366814 hasConcept C2777583451 @default.
• W2293366814 hasConcept C2778729363 @default.
• W2293366814 hasConcept C2779536868 @default.
• W2293366814 hasConcept C2911091166 @default.
• W2293366814 hasConcept C3019892230 @default.
• W2293366814 hasConcept C40677261 @default.
• W2293366814 hasConcept C502942594 @default.
• W2293366814 hasConcept C542903549 @default.
• W2293366814 hasConcept C71924100 @default.
• W2293366814 hasConcept C86803240 @default.
• W2293366814 hasConceptScore W2293366814C126322002 @default.
• W2293366814 hasConceptScore W2293366814C159654299 @default.
• W2293366814 hasConceptScore W2293366814C203014093 @default.
• W2293366814 hasConceptScore W2293366814C2777583451 @default.
• W2293366814 hasConceptScore W2293366814C2778729363 @default.
• W2293366814 hasConceptScore W2293366814C2779536868 @default.
• W2293366814 hasConceptScore W2293366814C2911091166 @default.
• W2293366814 hasConceptScore W2293366814C3019892230 @default.
• W2293366814 hasConceptScore W2293366814C40677261 @default.
• W2293366814 hasConceptScore W2293366814C502942594 @default.
• W2293366814 hasConceptScore W2293366814C542903549 @default.
• W2293366814 hasConceptScore W2293366814C71924100 @default.
• W2293366814 hasConceptScore W2293366814C86803240 @default.
• W2293366814 hasLocation W22933668141 @default.
• W2293366814 hasOpenAccess W2293366814 @default.
• W2293366814 hasPrimaryLocation W22933668141 @default.
• W2293366814 hasRelatedWork W2086111570 @default.
• W2293366814 hasRelatedWork W2109652607 @default.
• W2293366814 hasRelatedWork W2469350820 @default.
• W2293366814 hasRelatedWork W2512064655 @default.
• W2293366814 hasRelatedWork W2529971935 @default.
• W2293366814 hasRelatedWork W2535211482 @default.
• W2293366814 hasRelatedWork W2547251167 @default.
• W2293366814 hasRelatedWork W2553750310 @default.
• W2293366814 hasRelatedWork W2557014216 @default.
• W2293366814 hasRelatedWork W2559877690 @default.
• W2293366814 hasRelatedWork W2560065981 @default.
• W2293366814 hasRelatedWork W2562209710 @default.
• W2293366814 hasRelatedWork W2562486408 @default.
• W2293366814 hasRelatedWork W2571980445 @default.
• W2293366814 hasRelatedWork W2578953974 @default.
• W2293366814 hasRelatedWork W2584883488 @default.
• W2293366814 hasRelatedWork W2589693864 @default.
• W2293366814 hasRelatedWork W434671858 @default.
• W2293366814 hasRelatedWork W656370487 @default.
• W2293366814 hasRelatedWork W751703772 @default.
• W2293366814 isParatext "false" @default.
• W2293366814 isRetracted "false" @default.
• W2293366814 magId "2293366814" @default.
• W2293366814 workType "article" @default.